Showing results (361-370 of 531) with videos related to

Sort By:
Pageof 54
JACC. Heart Failure|June 7, 2022
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-PreservedJames L Januzzi, Javed Butler, Faiez Zannad, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
European Journal of Heart Failure|September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-ReducedMichael Böhm, Javed Butler, Amr Abdin, et al.
Circulation|June 28, 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without DiabetesGerasimos Filippatos, Javed Butler, Dimitrios Farmakis, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
JACC. Cardiovascular Interventions|November 21, 2015
Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart DiseaseTim P van de Hoef, Mauro Echavarría-Pinto, Martijn A van Lavieren, et al.
European Heart Journal|October 26, 2012
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesStuart J Pocock, Cono A Ariti, John J V McMurray, et al.
European Journal of Heart Failure|April 8, 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programmeJoão Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
Diabetes Care|May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) studyMichael R MacDonald, Mark C Petrie, Philip D Home, et al.
JACC. Heart Failure|October 11, 2020
Estimating the Lifetime Benefits of Treatments for Heart FailureJoão Pedro Ferreira, Kieran F Docherty, Susan Stienen, et al.
Pageof 54